Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.

Atorvastatin showed a reduction in the HR that was significant in model 1, borderline significant in model 2 (HR = 0.90, CI 0.79–1.02, p < 0.1) and not significant in model 3 (Table 2A ; fig. 1A, D ).

also in 6,822 other papers

Conclusion Simvastatin is associated with a strong reduction in the incidence of dementia and Parkinson's disease, whereas atorvastatin is associated with a modest reduction in incident dementia and Parkinson's disease, which shows only a trend towards significance. pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes pmc-license-ref CC BY Background Dementia is one of the major public health threats that individuals face as they age.

also in 1,643 other papers

We found that simvastatin is associated with a significant reduction in incident dementia and atorvastatin is associated with a more modest reduction that is of borderline significance.

also in 1,681 other papers